Form 4: Charles River Labs Director Acquires Shares
Insider Transaction Report
Reshema Kemps-Polanco, a Director at Charles River Laboratories, reported the acquisition of 1,973 shares of common stock on May 8, 2026.
Summary
- Reshema Kemps-Polanco, a Director at Charles River Laboratories International, Inc., acquired shares of common stock on May 8, 2026.
- The acquisition involved 1,438 shares purchased at $177.62 per share, bringing the total directly held shares to 4,028.
- An additional 535 shares were acquired under a grant in lieu of director service fees, also valued at $177.62 per share, increasing the total directly held shares to 4,563.
- These restricted stock units vest on May 8, 2027, or the business day prior to the company's next annual shareholder meeting.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's acquisition of stock, which can be interpreted as a sign of confidence, but it does not involve new strategic initiatives or financial performance data.
Positives
- Director acquisition of company stock can signal confidence in the company's future prospects.
- The acquisition of 1,973 shares by a director indicates continued investment in the company.
Future Outlook
The restricted stock units acquired by the director are set to vest on May 8, 2027, or the business day prior to the company's next annual shareholder meeting, indicating a medium-term outlook for these shares.
Industry Context
StockSavvy.ai notes that director stock acquisitions, particularly in the life sciences and contract research organization (CRO) sector, are often viewed as positive signals by the market, reflecting management's belief in the company's growth trajectory and stability.
Stakeholder Impact
- Shareholders may view the director's stock acquisition positively, potentially signaling confidence in the company's future performance.
- Employees may see this as a sign of stability and commitment from leadership.
Next Steps
- Vesting of restricted stock units on May 8, 2027, or the business day prior to the company's next annual shareholder meeting.
Key Dates
| Date | Description |
|---|---|
| 05/08/2026 | Earliest transaction date and date of stock acquisition. |
| 05/05/2026 | Commencement date for director service fees in lieu of which a grant was made. |
| 05/11/2026 | Date of signature for the filing. |
| 05/08/2027 | Vesting date for restricted stock units. |
Keywords
Form 4, SEC Filing, Insider Trading, Charles River Laboratories, CRL, Director, Stock Acquisition, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.